News

Lupin today announced its strategic collaboration with LABORATORIOS ERN S.A. (ERN), a well-established Spanish pharmaceutical company, for the launch of Luforbec� (beclometasone/formoterol) 100/6, a fixed dose combination in a pressurized metered dose inhaler, for the treatment of adult asthma and chronic obstructive pulmonary disease, in Spain. This collaboration combines Lupin`s global respiratory expertise and proven pMDI manufacturing excellence and ERN`s robust national reach and deep customer relationships, marking an exciting milestone in expanding high-quality respiratory care to patients across Spain.

Lupin and its alliance partner Natco Pharma (Natco) today announced the approval from the United States Food and Drug Administration (U.S. FDA) for Natco`s Abbreviated New Drug Application (ANDA) for Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials. Eribulin Mesylate Injection, 1 mg/2 mL (0.5 mg/mL) Single-Dose Vials is the bioequivalent to the reference listed drug (RLD) Halaven� Injection of Eisai, Inc. Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease and unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

Lupin today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its Ankleshwar facility in Gujarat, India, following closure of a product specific Pre-Approval Inspection from 02 March to 07 March 2026.

Lupin today announced that it has been featured for the first time in the Dow Jones Best-in-Class (DJBIC) Indices, underscoring the company`s strong commitment to sustainable, responsible, and ethical business practices. Lupin has been listed in both the DJBIC World Index and the DJBIC Emerging Markets Index. The DJBIC World Index ranks top-performing companies globally by strong ESG performance, while the DJBIC Emerging Markets Index highlights sustainability leaders across emerging economies. Lupin was previously ranked among the top 1% globally in the S&P Global Corporate Sustainability Assessment (CSA) 2025, achieving an industry-leading score of 91/100.The Dow Jones Best-in-Class Indices recognize companies that demonstrate exceptional performance across key Environmental, Social, and Governance (ESG) parameters, based on leading S&P Global CSA scores. Inclusion in these prestigious indices reinforces Lupin`s credibility with global investors, strengthens its competitive positioning, and places the company among a distinguished group of global leaders recognized for best-in-class sustainability performance.

Lupin announced that the Board of Directors of the Company at its meeting held on 7 May 2026, inter alia, have recommended the final dividend of Rs 18 per equity Share (i.e. 900%) , subject to the approval of the shareholders.